These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 24961502)

  • 1. A pilot study of the effects of eplerenone add-on therapy in patients taking renin-angiotensin system blockers.
    Kawada N; Isaka Y; Kitamura H; Rakugi H; Moriyama T
    J Renin Angiotensin Aldosterone Syst; 2015 Jun; 16(2):360-5. PubMed ID: 24961502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of eplerenone added to renin-angiotensin blockade in elderly hypertensive patients: the Jichi-Eplerenone Treatment (JET) study.
    Yano Y; Hoshide S; Tamaki N; Nagata M; Sasaki K; Kanemaru Y; Shimada K; Kario K
    J Renin Angiotensin Aldosterone Syst; 2011 Sep; 12(3):340-7. PubMed ID: 21393354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of aldosterone breakthrough on albuminuria during treatment with a direct renin inhibitor and combined effect with a mineralocorticoid receptor antagonist.
    Sato A; Fukuda S
    Hypertens Res; 2013 Oct; 36(10):879-84. PubMed ID: 23864056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of spironolactone in combination with angiotensin-converting enzyme inhibitors or Angiotensin receptor blockers in patients with proteinuria.
    Kim HY; Bae EH; Ma SK; Kim SW
    Kidney Blood Press Res; 2014; 39(6):573-80. PubMed ID: 25531940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats.
    Takeda Y; Zhu A; Yoneda T; Usukura M; Takata H; Yamagishi M
    Am J Hypertens; 2007 Oct; 20(10):1119-24. PubMed ID: 17903697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
    Epstein M; Williams GH; Weinberger M; Lewin A; Krause S; Mukherjee R; Patni R; Beckerman B
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):940-51. PubMed ID: 17699311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of blood pressure reduction by eplerenone in uncontrolled hypertension.
    Jansen PM; Frenkel WJ; van den Born BJ; de Bruijne EL; Deinum J; Kerstens MN; Arnoldus JH; Woittiez AJ; Wijbenga JA; Zietse R; Danser AH; van den Meiracker AH
    J Hypertens; 2013 Feb; 31(2):404-13. PubMed ID: 23249826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma aldosterone is increased in class 2 and 3 obese essential hypertensive patients despite drug treatment.
    Sarzani R; Guerra F; Mancinelli L; Buglioni A; Franchi E; Dessì-Fulgheri P
    Am J Hypertens; 2012 Jul; 25(7):818-26. PubMed ID: 22552267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma renin activity to plasma aldosterone concentration ratio correlates with night-time and pulse pressures in essential hypertensive patients treated with angiotensin-converting enzyme inhibitors/AT1 blockers.
    Spannella F; Giulietti F; Balietti P; Borioni E; Lombardi FE; Ricci M; Cocci G; Landi L; Sarzani R
    J Hypertens; 2017 Nov; 35(11):2315-2322. PubMed ID: 28614094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy.
    Bomback AS; Rekhtman Y; Klemmer PJ; Canetta PA; Radhakrishnan J; Appel GB
    J Am Soc Hypertens; 2012; 6(5):338-45. PubMed ID: 22995802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension.
    Andersen K; Weinberger MH; Constance CM; Ali MA; Jin J; Prescott MF; Keefe DL
    J Renin Angiotensin Aldosterone Syst; 2009 Sep; 10(3):157-67. PubMed ID: 19617271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of spironolactone to dual blockade of renin angiotensin system dramatically reduces severe proteinuria in renal transplant patients: an uncontrolled pilot study at 6 months.
    González Monte E; Andrés A; Polanco N; Toribio MJ; Santana R; Gutiérrez Martínez E; González J; Ramírez E; Hernández A; Morales E; Praga M; Morales JM
    Transplant Proc; 2010 Oct; 42(8):2899-901. PubMed ID: 20970564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eplerenone, an aldosterone blocker, is more effective in reducing blood pressure in patients with, than without, metabolic syndrome.
    Suzuki H; Shuto H; Shuto C; Ohara I; Inokuma S; Abe Y; Sukigara M
    Ther Adv Cardiovasc Dis; 2012 Aug; 6(4):141-7. PubMed ID: 22751654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension.
    Williams GH; Burgess E; Kolloch RE; Ruilope LM; Niegowska J; Kipnes MS; Roniker B; Patrick JL; Krause SL
    Am J Cardiol; 2004 Apr; 93(8):990-6. PubMed ID: 15081441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of eplerenone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric chronic hemodialysis patients - a pilot study.
    Shavit L; Neykin D; Lifschitz M; Slotki I
    Clin Nephrol; 2011 Nov; 76(5):388-95. PubMed ID: 22000559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats.
    Kang YS; Ko GJ; Lee MH; Song HK; Han SY; Han KH; Kim HK; Han JY; Cha DR
    Nephrol Dial Transplant; 2009 Jan; 24(1):73-84. PubMed ID: 18682491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can renin status predict the antihypertensive efficacy of eplerenone add-on therapy?
    Prisant LM; Krum H; Roniker B; Krause SL; Fakouhi K; He W
    J Clin Pharmacol; 2003 Nov; 43(11):1203-10. PubMed ID: 14551174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the T/L-type calcium channel blocker benidipine on albuminuria and plasma aldosterone concentration. A pilot study involving switching from L-type calcium channel blockers to benidipine.
    Tani S; Takahashi A; Nagao K; Hirayama A
    Int Heart J; 2014; 55(6):519-25. PubMed ID: 25310932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria.
    Ando K; Ohtsu H; Arakawa Y; Kubota K; Yamaguchi T; Nagase M; Yamada A; Fujita T;
    Hypertens Res; 2010 Jun; 33(6):616-21. PubMed ID: 20379190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone?
    Mahmud A; Mahgoub M; Hall M; Feely J
    Am J Hypertens; 2005 Dec; 18(12 Pt 1):1631-5. PubMed ID: 16364838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.